What's Happening?
The FDA has extended its review period for Eisai and Biogen's subcutaneous formulation of the Alzheimer's drug Leqembi by three months, now expecting a decision by August 24. This formulation, known as Leqembi Iqlik, is already approved for maintenance
therapy but is under review for use as a starting dose. The FDA's request for additional information has been classified as a major amendment, necessitating more time for evaluation. Despite the delay, Eisai and Biogen report no concerns from the FDA regarding the drug's approvability. Leqembi's growth has been hindered by modest efficacy and side effect concerns, similar to its competitor, Eli Lilly's Kisunla.
Why It's Important?
The delay in the FDA's decision on Leqembi Iqlik could impact Eisai and Biogen's market strategy, as the subcutaneous formulation is seen as a key driver for accelerating sales. The ability to administer the drug at home from the start could enhance patient convenience and adherence, potentially increasing market penetration. This development is crucial for Eisai and Biogen as they compete with Eli Lilly's Kisunla, which currently offers a more convenient once-monthly infusion. The outcome of this review could influence future regulatory strategies and competitive dynamics in the Alzheimer's treatment market.
What's Next?
Eisai and Biogen are expected to provide the additional information requested by the FDA to support their application for the subcutaneous formulation of Leqembi. The companies anticipate a decision by August 24, which will determine whether they can proceed with offering the subcutaneous version as an initial treatment option. If approved, this could significantly enhance the convenience and accessibility of Alzheimer's treatment, potentially increasing market adoption. The pharmaceutical industry will be closely monitoring this decision, as it may influence future regulatory strategies and competitive dynamics in the Alzheimer's treatment space.
